STOCK TITAN

Alterity Therapeutics (NASDAQ: ATHE) grants 18M unlisted options to staff

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Alterity Therapeutics Limited has issued 18,000,000 new unlisted options under its employee incentive scheme. These options have an exercise price of AUD 0.008 and expire on 9 January 2031, and on exercise will convert into ordinary fully paid ATH shares.

The options form a new unquoted security class that is not intended to be quoted on ASX, and all options in this class rank equally from the issue date of 15 January 2026. The filing also notes that this report is incorporated by reference into Alterity’s existing Form S-8 and Form F-3 registration statements.

Positive

  • None.

Negative

  • None.
 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of January 15, 2026

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

 

 

 

 

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1   Notification regarding unquoted securities - ATH

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Alterity Therapeutics Limited
     
  By: /s/ Julian Babarczy
    Julian Babarczy
    Chairman

 

Date: January 15, 2026

 

2

Exhibit 99.1 

 

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

 

Announcement Summary

 

 

Entity name

 

ALTERITY THERAPEUTICS LIMITED

 

Date of this announcement

Thursday January 15, 2026

 

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

 

ASX +security
code
  Security description   Total number of
+securities to be

issued/transferred
  Issue date
             
New class - code to be confirmed   Unlisted options expiring 9 January 2031 ex $0.008   18,000,000   15/01/2026

Refer to next page for full details of the announcement

 

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

1 / 6

 

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

 

 

Part 1 - Entity and announcement details

 

 

1.1 Name of entity
  
 ALTERITY THERAPEUTICS LIMITED
  
 We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

 

  1.2 Registered number type   Registration number
       
  ABN   37080699065

 

1.3 ASX issuer code
  
 ATH
  
 1.4 The announcement is
  
 New announcement
  
 1.5 Date of this announcement
  
 

15/1/2026

 

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

2 / 6

 

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

 

Part 2 - Issue details

 

 

2.1 The +securities the subject of this notification are:

 

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

 

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

 

does not have an existing ASX security code (“new class”)

 

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

3 / 6

 

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

 

 

Part 3C - number and type of +securities the subject of this notification (new class)

 

 

  ASX +security code   +Security description
  New class - code to be confirmed   Unlisted options expiring 9 January 2031 ex $0.008

 

  +Security type   ISIN code
       
  Options    

 

Date the +securities the subject of this notification were issued

 

15/1/2026

 

Will all the +securities issued in this class rank equally in all respects from their issue date?

 

Yes

 

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

 

No

 

Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?

 

No

 

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

 

   

 

Options Details

 

 

 

  +Security currency   Exercise price   Expiry date
  AUD - Australian Dollar   AUD 0.00800000   9/1/2031

 

Details of the existing class of +security that will be issued upon exercise or conversion of this new class of company option

 

ATH : ORDINARY FULLY PAID

 

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

 

 

  https://app.sharelinktechnologies.com/announcement-preview/asx/0e52c57244a1691e13a67c0caf2d50fb

 

Any other information the entity wishes to provide about the +securities the subject of this notification

 

   

 

Issue details

 

 

 

Number of +securities

18,000,000

 

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

4 / 6

 

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

 

 

Part 4 - +Securities on issue

 

 

Following the issue, conversion or payment up of the +securities the subject of this notification, the +securities of the entity will comprise:

 

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity’s current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

 

4.1 Quoted +securities (Total number of each +class of +securities issued and quoted on ASX)

 

   Total number of 
ASX +security code and description  +securities on issue 
ATH : ORDINARY FULLY PAID   10,875,416,329 
      
ATHO : OPTION EXPIRING 31-AUG-2026   931,232,089 
      
ATHOA : OPTION EXPIRING 26-FEB-2027   1,222,300,911 

 

4.2 Unquoted +securities (Total number of each +class of +securities issued but not quoted on ASX) 

 

   Total number of 
ASX +security code and description  +securities on issue 
ATHAAE : OPTION EXPIRING 29-NOV-2026 EX $0.0375   10,000,000 
      
ATHAAG : OPTION EXPIRING 29-NOV-2026 EX $0.0238   11,500,000 
      
ATHAE : OPTION EXPIRING 08-AUG-2030 EX $0.013   11,500,000 
      
ATHAF : OPTION EXPIRING 08-AUG-2030 EX USD 0.0086   312,400,200 
      
ATHAD : OPTION EXPIRING 01-JUL-2030 EX $0.01   15,000,000 
      
ATHAAK : OPTION EXPIRING 30-DEC-2027 EX $0.01   170,000,000 
      
ATHAAH : OPTION EXPIRING 19-DEC-2026 EX $0.0105   8,000,000 
      
ATHAB : OPTION EXPIRING 13-MAR-2029 EX US$0.0031   62,500,000 
      

ATHAA : OPTION EXPIRING 13-MAR-2029 EX $0.004

   20,166,667 
      
ATHAC : OPTION EXPIRING 21-MAR-2029 EX US$0.003   40,000,200 
      
New class - code to be confirmed : Unlisted options expiring 9 January 2031 ex $0.008   18,000,000 

 

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

5 / 6

 

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

 

 

Part 5 - Other Listing Rule requirements

 

 

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

Yes

 

5.1a Select the number of the applicable exception in Listing Rule 7.2

13

 

Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities

6 / 6

 

 

FAQ

What did Alterity Therapeutics (ATHE) announce in this Form 6-K?

Alterity Therapeutics announced the issue of new unlisted options under its employee incentive scheme and furnished this information as part of a Form 6-K, which is also incorporated by reference into its existing Form S-8 and Form F-3 registration statements.

How many new options did Alterity Therapeutics (ATHE) issue and on what date?

The company issued 18,000,000 new unlisted options on 15 January 2026 as part of its employee incentive scheme.

What are the key terms of the new Alterity Therapeutics (ATHE) options?

The new options are unlisted, have an exercise price of AUD 0.008 and an expiry date of 9 January 2031. Upon exercise, they will result in the issue of ordinary fully paid ATH shares.

Are the new Alterity Therapeutics (ATHE) options quoted on ASX?

No. The options are a new class of unquoted securities issued under an employee incentive scheme and are not intended to be quoted on ASX.

Do all the new Alterity Therapeutics (ATHE) options rank equally?

Yes. The filing states that all securities issued in this new option class rank equally in all respects from their issue date.

What is the impact on Alterity Therapeutics (ATHE) capital structure from this option issue?

The filing shows that these 18,000,000 unlisted options are added as a new unquoted class alongside existing quoted and unquoted securities, with ordinary fully paid shares (ATH) and various other option series already on issue.

Were any of the new Alterity Therapeutics (ATHE) options issued to key management personnel?

No. The document states that none of the options in this new class were issued to key management personnel or their associates.

Alterity Therapeutics Ltd

NASDAQ:ATHE

ATHE Rankings

ATHE Latest News

ATHE Latest SEC Filings

ATHE Stock Data

60.00M
17.99M
1.45%
0.59%
Biotechnology
Healthcare
Link
Australia
Melbourne